Financial reports
ARS
2023 FY
Annual report to shareholders
26 Apr 24
10-K
2023 FY
Annual report
7 Mar 24
10-Q
2023 Q3
Quarterly report
31 Oct 23
10-Q
2023 Q2
Quarterly report
31 Jul 23
10-Q
2023 Q1
Quarterly report
4 May 23
ARS
2022 FY
Annual report to shareholders
24 Mar 23
10-K
2022 FY
Annual report
2 Mar 23
10-Q
2022 Q3
Quarterly report
3 Nov 22
10-Q
2022 Q2
Quarterly report
1 Aug 22
10-Q
2022 Q1
Quarterly report
2 May 22
Current reports
8-K
DBV Technologies announces filing of 2023 Annual Report on Form 10-K and Universal Registration Document
8 Mar 24
8-K
DBV Technologies Reports Full Year 2023 Financial Results and Business Update
7 Mar 24
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
22 Dec 23
8-K
DBV Technologies Announces 2-Year Results from Ongoing Phase 3 Open-Label Extension to the EPITOPE Trial (EPOPEX) of Viaskin™ Peanut in Toddlers
9 Nov 23
8-K/A
Departure of Directors or Certain Officers
6 Nov 23
8-K/A
Departure of Directors or Certain Officers
2 Nov 23
8-K
Termination of a Material Definitive Agreement
31 Oct 23
8-K
DBV Technologies Announces Appointment of Virginie Boucinha as Chief Financial Officer
16 Oct 23
8-K
Results of Operations and Financial Condition
31 Jul 23
8-K
DBV Technologies Announces New England Journal of Medicine Publication of Phase 3 EPITOPE Trial Data Evaluating Viaskin™ Peanut in Toddlers
11 May 23
Registration and prospectus
S-8
Registration of securities for employees
20 Nov 23
S-3
Shelf registration
6 Apr 23
424B3
Prospectus supplement
11 Aug 22
424B3
Prospectus supplement
11 Aug 22
S-3
Shelf registration
1 Aug 22
S-3
Shelf registration
1 Aug 22
F-6EF
Automatic registration for ADRs (foreign)
18 Jul 22
F-6EF
Automatic registration for ADRs (foreign)
25 May 22
424B5
Prospectus supplement for primary offering
2 May 22
S-3
Shelf registration
30 Jun 21
Proxies
DEF 14A
Definitive proxy
26 Apr 24
PRE 14A
Preliminary proxy
8 Apr 24
DEF 14A
Definitive proxy
24 Mar 23
PRE 14A
Preliminary proxy
8 Mar 23
DEFA14A
Additional proxy soliciting materials
26 Apr 22
DEFA14A
Additional proxy soliciting materials
26 Apr 22
DEF 14A
Definitive proxy
25 Apr 22
PRER14A
Preliminary revised proxy
14 Apr 22
PRE 14A
Preliminary proxy
6 Apr 22
DEFA14A
Additional proxy soliciting materials
29 Apr 21
Other
EFFECT
Notice of effectiveness
18 Apr 23
CORRESP
Correspondence with SEC
13 Apr 23
UPLOAD
Letter from SEC
13 Apr 23
EFFECT
Notice of effectiveness
12 Aug 22
EFFECT
Notice of effectiveness
12 Aug 22
CORRESP
Correspondence with SEC
9 Aug 22
CORRESP
Correspondence with SEC
9 Aug 22
UPLOAD
Letter from SEC
5 Aug 22
UPLOAD
Letter from SEC
5 Aug 22
EFFECT
Notice of effectiveness
19 Jul 21
Ownership
4
Daniel Tasse
11 Mar 24
SC 13G/A
Venrock Healthcare Capital Partners II, L.P.
14 Feb 24
SC 13G/A
BRAIDWELL LP
14 Feb 24
4
Adora Ndu
8 Feb 24
4
Pharis Mohideen
19 Dec 23
4
Virginie Boucinha
22 Nov 23
4
Daniel Tasse
22 Nov 23
4
Pharis Mohideen
22 Nov 23
3
Virginie Boucinha
7 Nov 23
4
TIMOTHY E MORRIS
28 Aug 23